Recent Updates
Recently added Catalysts
APYX Positive Sentiment Score: 65/100

Apyx Medical Corporation to Release First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025

Key Takeaway: Apyx Medical Corporation has announced that it will release its financial results for the first quarter of fiscal year 2025 on May 8, 2025. The company will conduct a conference call to discuss these results and engage in a question-and-answer session. This event underscores the company's ongoing operations and communication efforts with investors.

Market Sentiment Analysis

POSITIVE FACTORS

  • Upcoming financial results indicate ongoing business activities.
  • Management is actively engaging investors through a conference call.
  • The company has a strong technical foundation with products supported by clinical publications.

Full Press Release Details

CLEARWATER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the first quarter of fiscal year 2025 will be released before markets open on Thursday, May 8th.
Management will host a conference call at 8:00 a.m. Eastern Time on Thursday, May 8th to discuss the results of the quarter, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 63341. Participants should ask for the “Apyx Medical Corporation Call”. A live webcast of the call will be accessible via the following link: Apyx Medical Earnings Webcast and via the Investor Relations section of the Company’s website, where it will be archived for future reference.
Investor Relations Contact:
About Apyx Medical Corporation:
Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical publications. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com

Frequently Asked Questions

When will Apyx Medical's Q1 fiscal results be released?

The financial results for Q1 fiscal year 2025 will be released on May 8th.

What time is the Apyx Medical conference call scheduled?

The conference call is set for 8:00 a.m. Eastern Time on May 8th.

How can I listen to Apyx Medical's conference call?

Call 800-717-1738 or view the live webcast via their website.

What technology does Apyx Medical produce?

Apyx Medical produces helium plasma and radiofrequency technology, including Renuvion®.

What support exists for Renuvion and J-Plasma effectiveness?

Their effectiveness is backed by over 90 clinical publications.

Last updated: Apr 24, 2025